The Medicare GLP-1 Bridge began on July 1, 2026 and runs through December 31, 2027. Eligible people with Medicare Part D pay $50 a month for Foundayo (tablet), Wegovy (injection or tablet) or Zepbound (KwikPen only). Zepbound vials and single-dose pens are not covered. It is a CMS demonstration that operates outside the ordinary Part D benefit, and your Part D plan does not have to opt in. Sources: Medicare fact sheet, June 2026, Medicare.gov, CMS. Read November 6, 2026.
Do not qualify, or want to compare other routes? Your doctor is the first call. You can also compare recorded prices and terms for every program we list. Programs that sell compounded medication are not part of Medicare, and compounded drugs are not FDA-approved. See what FDA says.
This post started as our launch-day report, and we have kept its checklist and the common points of confusion, corrected to what CMS and Medicare have published since. In short: confirm your plan type, talk to your doctor, let the pharmacy run the claim, and have your doctor complete the prior authorization when asked. CMS says the decision comes within 72 hours of submission.
The Bridge in one paragraph
Part D excludes drugs when used for weight loss. The Bridge is a CMS demonstration under the Social Security Amendments of 1967, run outside the Part D benefit, that gave eligible Part D beneficiaries access to certain GLP-1s starting July 1, 2026. CMS says participating manufacturers provide the drugs at a net price of $245 per monthly supply, and you pay $50. It was first set to end December 31, 2026, and CMS extended it through December 31, 2027. For the full guide, with every rule and source, see our Medicare GLP-1 Bridge guide.
What started on July 1
- Dispensing: eligible claims could be filled from July 1. CMS says pharmacies do not need to opt in, and claims go electronically to the Bridge processor.
- No sign-up window: there is no annual enrollment period for the Bridge itself. You need Part D coverage under an eligible plan type, and your doctor and pharmacy start the process.
- One processor: in 2026 CMS uses a single central processor for prior authorization, claims and pharmacy payment. Part D sponsors do not have a financial or administrative role.
- How many people: CMS has not published an estimate in the pages we read. KFF's analysis of 2023 data put it at about 3.8 million people who appeared to meet the rules. That is an estimate, not an enrollment count.
Who is eligible
The Medicare fact sheet lists four requirements. You must meet all of them:
- You have Medicare Part D drug coverage, under a standalone drug plan or a Medicare health plan that includes drug coverage. You are not eligible if your only Medicare coverage is through certain special plan types, such as private fee-for-service plans, cost contract plans or a PACE organization.
- You are not eligible to receive a GLP-1 through your Medicare drug plan. If your plan has been paying for a GLP-1 for any reason, you need to keep getting it through your plan.
- You do not have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. If you have one of these, contact your drug plan, which may already cover a GLP-1 for you.
- You are at least 18 and meet one of the BMI rules below.
The BMI rules, which CMS says apply to your BMI when you started GLP-1 therapy:
- BMI of 35 or higher
- BMI of 30 or higher, with certain types of heart failure, high blood pressure that is hard to control, or chronic kidney disease (stage 3a or above)
- BMI of 27 or higher, with prediabetes, or a prior heart attack, stroke or blocked arteries in your legs or arms
What it covers
| Drug | Form covered | Bridge copay | Weight loss in trials |
|---|---|---|---|
| Foundayo (orforglipron) | Tablet | $50/month | up to 12.4% of body weight (ATTAIN-1, top dose) |
| Wegovy (semaglutide) | Injection or tablet | $50/month | 15-17% of body weight |
| Zepbound (tirzepatide) | KwikPen only; vials and single-dose pens are NOT covered | $50/month | 20-22% of body weight |
Ozempic, Mounjaro and compounded drugs are not on the list. Compounded drugs are not FDA-approved.
The $50 does not count toward your Part D deductible or yearly out-of-pocket limit, and these drugs are not eligible for the Medicare Prescription Payment Plan. Extra Help cannot lower it, and CMS says coupons and discount programs may not be applied.
Your first-fill checklist
Step 1: Check your eligibility with your prescriber. Go through the four requirements above together. Ask your prescriber which BMI rule applies to you, and to confirm that any listed condition is in your records. By completing the form, the prescriber attests under penalty of perjury that the information is accurate, and CMS may check it against Medicare data.
Step 2: Check your plan type. You do not need to confirm that your plan is "participating," because Part D plans are not participants. You do need an eligible plan type. Call 1-800-MEDICARE (1-800-633-4227; TTY 1-877-486-2048) if you are unsure.
Step 3: Choose a drug with your doctor. All three are $50 a month under the Bridge. Foundayo is a once-daily tablet. Wegovy comes as a weekly injection or a daily tablet. Zepbound is a weekly injection, and only the KwikPen counts. Trial results are not a head-to-head comparison, and the right one depends on your history and how you tolerate it. See Wegovy vs Zepbound and our Foundayo guide.
Step 4: Your doctor sends the prescription. A diagnosis code and a note directing the pharmacy to the Bridge are recommended, not required. A Part D denial is not required first.
Step 5: Give the pharmacy your Medicare number. If you do not have your card, the pharmacist can look it up with the last four digits of your Social Security Number.
Step 6: Your doctor completes the prior authorization. The pharmacy sends the request, typically within 24 to 72 hours. If none arrives in 72 hours, the doctor can fax the form directly. CMS says doctors should not submit it before the pharmacy claim, because that returns a "patient not found" error.
Step 7: Pick up the medicine and pay $50. You get a letter from Medicare confirming coverage. Refills do not need a new approval as long as you stay on the same drug, even if your dose changes. Each fill is a single 28 or 30 day supply: CMS says 60-day, 90-day and partial fills are not available.
Three common points of confusion
1. The Bridge does not cover Ozempic or Mounjaro
The Bridge list is Foundayo, Wegovy and Zepbound KwikPen. Ozempic and Mounjaro are not on it.
If you take Ozempic or Mounjaro through your Part D plan: stay there. Medicare says to keep getting a GLP-1 through your plan if it has been paying for one for any reason, and CMS says a person who received a GLP-1 through Part D in 2026 is not eligible for the Bridge. Your plan's cost sharing applies, and plans do not have to match $50.
If you pay for Ozempic or Mounjaro yourself for weight loss: ask your prescriber whether one of the three Bridge drugs fits and whether you meet the rules. See Ozempic vs Wegovy and Mounjaro for weight loss.
2. Compounded medications are not covered
The Bridge list names three FDA-approved brands. Compounded semaglutide and tirzepatide are not on it. FDA says compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are marketed.
If you use a compounded product and may qualify: ask your prescriber whether moving to a Bridge drug makes sense. Recorded compounded subtotals start at $49 for semaglutide and $99 for tirzepatide on monthly plans, and those are partial subtotals. Moving from a compounded dose to a brand dose is a decision for your prescriber. Our switching guide covers what to ask.
If you use a compounded product and do not qualify: the Bridge changes nothing for you. See the cheapest programs page for recorded prices, dates and terms, and FDA's concerns on our FDA actions tracker.
3. Your Part D plan does not run this
Calling your plan may get you little. CMS says Part D sponsors are not participants, do not have to opt in, and must not advertise the Bridge or include it in plan benefit materials. CMS encourages plans to direct you to 1-800-MEDICARE, and it strongly encourages them to help route a weight-management claim to the Bridge.
If a pharmacy says "your plan doesn't have this": the question is not whether your plan has it. Ask the pharmacist to send the claim to the Bridge. CMS's pharmacy page has the routing details and a help desk at 844-673-0910. Prescribers can call 855-273-0102.
If you have a Part D-covered use: plans must still cover GLP-1s for those uses and must not push you toward the Bridge. Their exception and appeal processes still apply.
If you do not qualify
The tiers leave out a meaningful group: for example, Part D enrollees with a BMI of 27 to 29.9 and none of the listed conditions, or a BMI of 30 to 34.9 with only conditions that are not listed. Talk to your doctor first. These are other paths to check:
- Your drug plan, if you have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. It may already cover a GLP-1.
- Manufacturer self-pay: NovoCare (Wegovy pen $199 for the first two fills through December 31, 2026, then $349 a month), LillyDirect (Zepbound KwikPen and vials from $299, Foundayo $149-$299 by dose). Read each program's terms for people on government coverage. Manufacturer savings cards exclude them.
- Medicare.gov's other suggestions: manufacturer payment assistance, state help with drug costs, mail-order pharmacy prices, and the Medicare Prescription Payment Plan.
- Compounded programs: compounded drugs are not FDA-approved, and FDA says they should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Listed programs with recorded prices, in our published order, are below. See the cheapest programs page for dates and terms.
- Embody: semaglutide $49/mo on a 12-month plan, $79/mo monthly; tirzepatide $99/mo on a 12-month plan, $129/mo monthly.
- TrimRx: semaglutide From $179 (seller says GLP-1), term not stated; tirzepatide From $279 (seller says GLP-1 + GIP), term not stated.
- SnagRx: semaglutide $59/mo, sale price, term not stated; tirzepatide $109/mo, sale price, term not stated.
- ShedRx: semaglutide $175/mo; tirzepatide $225/mo.
- bmiMD: semaglutide $159/mo; tirzepatide $249/mo.
Check your records with your prescriber. If you may have prediabetes but have never been tested, ask whether an A1C test makes sense. If you take two medicines for high blood pressure and it remains high, ask whether your records say so, because that is how CMS describes uncontrolled hypertension. The point is an accurate record, not a qualifying one: your prescriber attests to the form under penalty of perjury.
The 503B proposal, for readers on compounded medication
FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, and later extended the comment period to July 30, 2026. It is a proposal about outsourcing facilities, and it does not change the Bridge. We found no final decision as of November 6, 2026. For its status, see our FDA actions tracker and 503B explainer.
FAQ
Do I need to switch Part D plans? CMS says Part D sponsors do not have to opt in for eligible people to get these drugs. Check your plan type against the exclusions above.
Do I need to switch pharmacies to get the Bridge copay? CMS says pharmacies do not need to opt in. The pharmacy needs your Medicare number and sends the claim electronically to the Bridge processor. If your pharmacy is unsure, it can call the CMS help desk at 844-673-0910.
Can I use my current Wegovy or Zepbound prescription? Your doctor needs to send a prescription for a covered form, and complete the prior authorization when asked. A Zepbound vial or single-dose pen prescription does not qualify. Only the KwikPen does.
How long does the prior authorization take? CMS says the pharmacy typically sends its request within 24 to 72 hours, and that the decision comes within 72 hours of submission. It is mailed to you and sent to your prescriber.
What if my prior authorization is denied? CMS says there is no appeals process under the Bridge. Your prescriber may resubmit the form if the original held incorrect information, or if updated or additional information is available. A request that attests to type 2 diabetes, moderate to severe sleep apnea or the listed liver disease will be denied, and those people should use their Part D plan.
Does it cover Rybelsus or Ozempic? They are not on the Medicare fact sheet's list of Bridge drugs. If you take one through your drug plan, you need to keep getting it through your plan.
Can I switch drugs? Medicare.gov says prior authorization is valid through December 31, 2027, including for refills and dose changes, unless you switch GLP-1 drugs. A switch needs a new prior authorization.
Does Extra Help lower the $50? Medicare.gov says Extra Help cannot lower it.
What if my weight drops below the BMI threshold? CMS looks at your BMI when you started therapy, not your current BMI. Its example is a person with a BMI of 37 at the start and 34 at the time of the request, who still meets the rule. The authorization is valid through December 31, 2027 unless you change drugs.
Is the Bridge available if I use VA prescription coverage? The Bridge requires Part D coverage under an eligible plan type. VA coverage on its own does not meet that rule. If you have both, ask 1-800-MEDICARE.
What about Medicare Advantage plans? Medicare.gov lists Medicare Advantage coordinated care plans with drug coverage (HMO, HMOPOS, and Local and Regional PPO) and Special Needs Plans as eligible. Private fee-for-service plans are not.
What happens after December 31, 2027? CMS has not said. Its BALANCE page refers only to a potential implementation in Part D, with no date. See our guide.
For every rule and source in one place, see our Medicare GLP-1 Bridge guide. For recorded prices, see the cheapest GLP-1 programs page. If you are in the gap: cheapest compounded semaglutide and cheapest compounded tirzepatide.
